Market capitalization | $1.29m |
Enterprise Value | $66.52m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.05 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-20.93m |
Free Cash Flow (TTM) Free Cash Flow | $-13.28m |
Cash position | $3.43m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast AzurRx BioPharma, Inc.:
1 Analyst has issued a forecast AzurRx BioPharma, Inc.:
Mar '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.07 -0.07 |
30%
30%
|
|
EBITDA | -21 -21 |
187%
187%
|
EBIT (Operating Income) EBIT | -21 -21 |
184%
184%
|
Net Profit | -6.16 -6.16 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
Head office | United States |
CEO | James Sapirstein |
Employees | 9 |
Founded | 2014 |
Website | enterothera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.